Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route (Descending) Package Effective Date Package Discontinuation Date Status
31722-0261-21 31722-0261 LENALIDOMIDE LENALIDOMIDE 20.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral May 11, 2023 In Use
31722-0262-01 31722-0262 LENALIDOMIDE LENALIDOMIDE 25.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral May 11, 2023 In Use
31722-0262-21 31722-0262 LENALIDOMIDE LENALIDOMIDE 25.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral May 11, 2023 In Use
42291-0016-30 42291-0016 ANASTROZOLE ANASTROZOLE 1.0 mg/1 Hormonal Therapy Aromatase Inhibitor Oral Feb. 6, 2023 In Use
42291-0016-90 42291-0016 ANASTROZOLE ANASTROZOLE 1.0 mg/1 Hormonal Therapy Aromatase Inhibitor Oral Feb. 6, 2023 In Use
42388-0023-26 42388-0023 Cabozantinib CABOMETYX 60.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral April 25, 2016 In Use
42388-0023-36 42388-0023 Cabozantinib CABOMETYX 60.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Nov. 16, 2017 In Use
42388-0023-37 42388-0023 Cabozantinib CABOMETYX 60.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Oct. 3, 2018 In Use
42388-0023-46 42388-0023 Cabozantinib CABOMETYX 60.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Jan. 9, 2023 In Use
42388-0023-57 42388-0023 Cabozantinib CABOMETYX 60.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Jan. 9, 2023 In Use
42388-0024-26 42388-0024 Cabozantinib CABOMETYX 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral April 25, 2016 In Use
42388-0024-37 42388-0024 Cabozantinib CABOMETYX 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Feb. 27, 2019 In Use
42388-0024-46 42388-0024 Cabozantinib CABOMETYX 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Jan. 9, 2023 In Use
42388-0024-57 42388-0024 Cabozantinib CABOMETYX 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Jan. 9, 2023 In Use
42388-0025-26 42388-0025 Cabozantinib CABOMETYX 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral April 25, 2016 In Use
42388-0025-37 42388-0025 Cabozantinib CABOMETYX 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Feb. 27, 2019 In Use
42388-0025-46 42388-0025 Cabozantinib CABOMETYX 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Jan. 9, 2023 In Use
42388-0025-57 42388-0025 Cabozantinib CABOMETYX 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Jan. 9, 2023 In Use
00480-1241-28 00480-1241 Lenalidomide Lenalidomide 2.5 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral March 8, 2023 In Use
00480-1245-21 00480-1245 Lenalidomide Lenalidomide 20.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral March 8, 2023 In Use
10135-0774-01 10135-0774 Prednisone Prednisone 1.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Feb. 1, 2023 In Use
10135-0775-01 10135-0775 Prednisone Prednisone 2.5 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Feb. 1, 2023 In Use
10135-0779-01 10135-0779 Prednisone Prednisone 50.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Feb. 1, 2023 In Use
35356-0197-30 35356-0197 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Nov. 10, 2010 Dec. 31, 2015 In Use
35356-0197-65 35356-0197 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Nov. 10, 2010 In Use

Found 10,000 results in 7 milliseconds — Export these results